Showing results (41-50 of 55) with videos related to
Sort By:
Pageof 6
Bioorganic & Medicinal Chemistry|December 31, 2010
Synthesis, structure, theoretical and experimental in vitro antioxidant/pharmacological properties of α-aryl, N-alkyl nitrones, as potential agents for the treatment of cerebral ischemiaAbdelouahid Samadi, Elena Soriano, Julia Revuelta, et al.Molecules (Basel, Switzerland)|May 18, 2016
Synthesis and Biological Evaluation of Benzochromenopyrimidinones as Cholinesterase Inhibitors and Potent Antioxidant, Non-Hepatotoxic Agents for Alzheimer's DiseaseYoussef Dgachi, Oscar M Bautista-Aguilera, Mohamed Benchekroun, et al.International Journal of Molecular Sciences|August 12, 2023
The Proof-of-Concept of MBA121, a Tacrine-Ferulic Acid Hybrid, for Alzheimer's Disease TherapyEmelina R Rodríguez-Ruiz, Raquel Herrero-Labrador, Ana P Fernández-Fernández, et al.Journal of Medicinal Chemistry|October 14, 2016
The Antioxidant Additive Approach for Alzheimer's Disease Therapy: New Ferulic (Lipoic) Acid Plus Melatonin Modified Tacrines as Cholinesterases Inhibitors, Direct Antioxidants, and Nuclear Factor (Erythroid-Derived 2)-Like 2 ActivatorsMohamed Benchekroun, Alejandro Romero, Javier Egea, et al.Chemmedchem|January 26, 2016
Synthesis and Biological Assessment of Racemic Benzochromenopyrimidinimines as Antioxidant, Cholinesterase, and Aβ1-42 Aggregation Inhibitors for Alzheimer's Disease TherapyYoussef Dgachi, Lhassane Ismaili, Damijan Knez, et al.International Journal of Molecular Sciences|June 4, 2020
Acetylcholinesterase Inhibition of Diversely Functionalized Quinolinones for Alzheimer's Disease TherapyÓscar M Bautista-Aguilera, Lhassane Ismaili, Mourad Chioua, et al.European Journal of Medicinal Chemistry|June 30, 2018
Tacripyrimidines, the first tacrine-dihydropyrimidine hybrids, as multi-target-directed ligands for Alzheimer's diseaseMourad Chioua, Eleonora Buzzi, Ignacio Moraleda, et al.European Journal of Medicinal Chemistry|December 6, 2016
Tetrahydropyranodiquinolin-8-amines as new, non hepatotoxic, antioxidant, and acetylcholinesterase inhibitors for Alzheimer's disease therapyYoussef Dgachi, Olga Sokolov, Vincent Luzet, et al.ACS Chemical Neuroscience|August 29, 2024
Discovery of New Highly Potent Histamine H3 Receptor Antagonists, Calcium Channel Blockers, and Acetylcholinesterase InhibitorsRim Malek, Kinga Sałat, Perle Totoson, et al.ACS Omega|January 1, 2020
Chromenones as Multineurotargeting Inhibitors of Human EnzymesCarina Lemke, Joscha Christmann, Jiafei Yin, et al.Pageof 6